At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and Pluvicto eligibility, with NCCN no longer requiring conventional imaging first. He identifies guideline gaps regarding quantification and response assessment, highlighting upcoming PCWG4 and SPARC…
Federal agencies, including the FDA and the EPA, were ordered to accelerate approval of domestic manufacturing plants.
At the 2025 UCSF-UCLA PSMA Conference, Wolfgang Fendler demonstrates how PSMA-PET provides spatial biomarkers predicting overall survival in prostate cancer. Drawing from the 10,000+ patient…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Neal…
More than 70 million U.S. adults live with physical, sensory, cognitive, developmental, or intellectual disabilities. These individuals are more than twice as likely than other…
The FDA is asking some of its recently fired staff responsible for critically important funding negotiations with drugmakers to return
AUA 2025 bladder preservation in patients with clinical complete response to neoadjuvant chemotherapy, cT2 bladder cancer patients,
The FDA is asking some of its recently fired staff responsible for critically important funding negotiations with drugmakers to return
AUA 2025 bladder preservation in patients with clinical complete response to neoadjuvant chemotherapy, cT2 bladder cancer patients,
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul…
The number of US employees offered ICHRAs continues to grow. Yet, headwinds – including competition, individual coverage market uncertainty, and complexity – may hamper the…
